Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Should You Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s share price gapped down prior to trading on Thursday . The stock had previously closed at $32.36, but opened at $31.33. Dyne Therapeutics shares last traded at $31.93, with a volume of 67,167 shares trading hands.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Guggenheim lifted their price target on Dyne Therapeutics from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, August 15th. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an "overweight" rating to a "neutral" rating and reduced their target price for the stock from $43.00 to $35.00 in a report on Thursday. Stifel Nicolaus raised their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a "buy" rating in a research note on Friday, August 16th. Morgan Stanley lifted their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an "overweight" rating in a report on Wednesday, August 14th. Finally, Oppenheimer restated an "outperform" rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $50.60.

Dyne Therapeutics Stock Performance

The business has a 50 day moving average price of $36.92 and a 200-day moving average price of $34.66. The company has a market capitalization of $2.72 billion, a price-to-earnings ratio of -8.15 and a beta of 1.05.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.02. As a group, equities analysts predict that Dyne Therapeutics, Inc. will post -2.96 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other news, Director Dirk Kersten sold 79,411 shares of the stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the transaction, the director now owns 234,127 shares of the company's stock, valued at $8,533,929.15. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Director Dirk Kersten sold 79,411 shares of the business's stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the sale, the director now owns 234,127 shares in the company, valued at $8,533,929.15. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Susanna Gatti High sold 8,976 shares of the company's stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total transaction of $308,864.16. Following the transaction, the chief operating officer now owns 131,636 shares in the company, valued at approximately $4,529,594.76. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 158,975 shares of company stock worth $5,693,789 in the last quarter. Company insiders own 20.77% of the company's stock.

Institutional Trading of Dyne Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC boosted its position in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company's stock valued at $26,000 after buying an additional 669 shares during the last quarter. Values First Advisors Inc. purchased a new position in Dyne Therapeutics during the 3rd quarter worth $62,000. Amalgamated Bank grew its stake in shares of Dyne Therapeutics by 39.9% in the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company's stock worth $99,000 after acquiring an additional 796 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Dyne Therapeutics by 24.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company's stock valued at $123,000 after purchasing an additional 709 shares during the last quarter. Finally, Ameritas Investment Partners Inc. lifted its position in shares of Dyne Therapeutics by 28.0% during the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company's stock valued at $167,000 after purchasing an additional 1,291 shares in the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.